{'52WeekChange': -0.4654088,
 'SandP52WeekChange': None,
 'address1': '1100 Massachusetts Avenue',
 'address2': 'Floor 4',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 0.86,
 'askSize': 1300,
 'averageDailyVolume10Day': 474500,
 'averageVolume': 561628,
 'averageVolume10days': 474500,
 'beta': 1.774789,
 'beta3Year': None,
 'bid': 0.83,
 'bidSize': 800,
 'bookValue': -0.039,
 'category': None,
 'circulatingSupply': None,
 'city': 'Cambridge',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 0.8599,
 'dayLow': 0.8208,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': 0.012,
 'enterpriseToRevenue': -0.378,
 'enterpriseValue': -505113,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fax': '617 453 1001',
 'fiftyDayAverage': 0.90085715,
 'fiftyTwoWeekHigh': 1.68,
 'fiftyTwoWeekLow': 0.6,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 37909621,
 'forwardEps': -0.76,
 'forwardPE': -1.0921053,
 'fromCurrency': None,
 'fullTimeEmployees': 25,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'headSymbol': None,
 'heldPercentInsiders': 0.03514,
 'heldPercentInstitutions': 0.50639,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/infi.com',
 'longBusinessSummary': 'Infinity Pharmaceuticals, Inc., a biopharmaceutical '
                        'company, focuses on developing novel medicines for '
                        'people with cancer. It offers IPI-549, an orally '
                        'administered, clinical-stage, immuno-oncology product '
                        'candidate that selectively inhibits the enzyme '
                        'phosphoinositide-3-kinase-gamma Its product candidate '
                        'is IPI-549, an orally administered clinical-stage '
                        'immuno-oncology product candidate that inhibits the '
                        'enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma), '
                        'which is in Phase 1/1b clinical study. The company '
                        'has strategic alliances with Intellikine, Inc. to '
                        'discover, develop, and commercialize pharmaceutical '
                        'products targeting the delta and/or gamma isoforms of '
                        'PI3K; Verastem, Inc. to research, develop, '
                        'commercialize, and manufacture duvelisib and products '
                        'containing duvelisib, as well as duvelisib program '
                        'for patients with relapsed or refractory chronic '
                        'lymphocytic leukemia or small lymphocytic lymphoma; '
                        'and PellePharm, Inc. to develop and commercialize '
                        'rights to its hedgehog inhibitor program, IPI-926, a '
                        'clinical-stage product candidate, as well as '
                        'collaboration agreements with Arcus Biosciences, '
                        'Inc., F. Hoffmann-La Roche Ltd., and Bristol-Myers '
                        'Squibb Company. Infinity Pharmaceuticals, Inc. is '
                        'headquartered in Cambridge, Massachusetts.',
 'longName': 'Infinity Pharmaceuticals, Inc.',
 'market': 'us_market',
 'marketCap': 47669888,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_1208927',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -44199000,
 'nextFiscalYearEnd': 1640908800,
 'open': 0.85,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': -0.01,
 'phone': '617 453 1000',
 'previousClose': 0.85,
 'priceHint': 4,
 'priceToBook': None,
 'priceToSalesTrailing12Months': 35.707783,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 0.8599,
 'regularMarketDayLow': 0.8208,
 'regularMarketOpen': 0.85,
 'regularMarketPreviousClose': 0.85,
 'regularMarketPrice': 0.85,
 'regularMarketVolume': 238620,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 57433600,
 'sharesPercentSharesOut': 0.0008,
 'sharesShort': 46726,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 35725,
 'shortName': 'Infinity Pharmaceuticals, Inc.',
 'shortPercentOfFloat': 0.0011999999,
 'shortRatio': 0.22,
 'startDate': None,
 'state': 'MA',
 'strikePrice': None,
 'symbol': 'INFI',
 'threeYearAverageReturn': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -0.774,
 'twoHundredDayAverage': 1.0341727,
 'underlyingExchangeSymbol': None,
 'underlyingSymbol': None,
 'uuid': '8cd68403-20bb-3642-a9b8-c76813f0dbd8',
 'volume': 238620,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.infi.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '02138'}